Transcept Pharmaceuticals, Inc. (TSPT) Reports Q1 EPS Loss of $0.14, Tops Consensus by $0.13

Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) reported Q1 EPS of ($0.14), $0.13 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $3.1 million versus the consensus estimate of $3.1 million.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Nortech Systems, Inc. (NSYS) Tops Q2 EPS by 11c
• Acrivon Therapeutics, Inc. (ACRV) Tops Q2 EPS by 21c